文献速递白血病

整合临床特征与遗传因素可增强成人急性髓系白血病生存预测

Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究在巴西圣保罗167例强化治疗的非急性早幼粒细胞白血病AML患者中建立适配遗传风险(AGR),允许细胞遗传学或分子数据缺失,并与Cox模型筛选的临床参数(年龄>45岁、白细胞<1.5或>30.0×10³/μL、白蛋白<3.8 g/dL)组合成生存AML评分(SAMLS),在巴西Ribeirão Preto(n=145)和英国Oxford(n=157)两个独立队列中验证。

要点

  • AGR在FMRP队列OS(P=.037)和OUH队列OS(P=.012)及FMRP无病生存(P=.04)有统计学意义。
  • SAMLS在训练队列OS差异显著(P<.001),FMRP队列P=.0018,OUH队列P<.001。
  • SAMLS结合AGR与临床参数,是AML风险评估的准确工具。

核心结论

  • 结合新型AGR评估与临床参数的SAMLS是AML风险评估的准确工具。

研究设计与样本

  • 训练数据集为巴西圣保罗Faculdade de Medicina da Universidade de São Paulo入组的167例强化治疗的非急性早幼粒细胞白血病AML患者,以ELN2017为比较标准。
  • 验证队列为巴西Faculdade de Medicina de Ribeirão Preto(FMRP,n=145)和英国Oxford University Hospitals(OUH,n=157)两个独立测试队列。

主要发现

  • AGR对两个测试队列的总生存均有统计学意义(FMRP,P=.037;OUH,P=.012),对FMRP的无病生存有统计学意义(P=.04)。
  • SAMLS中的临床预后特征为年龄>45岁、白细胞计数<1.5或>30.0×10³/μL、低白蛋白水平<3.8 g/dL,这些特征在全部3个队列中均与更差的总生存相关。
  • SAMLS在训练队列的总生存差异显著(P<.001),在测试队列亦显著(FMRP,P=.0018;OUH,P<.001)。

关键数值与推荐

  • AGR在FMRP队列总生存P=.037,在OUH队列总生存P=.012,在FMRP队列无病生存P=.04。
  • SAMLS在训练队列总生存P<.001,FMRP队列P=.0018,OUH队列P<.001。
  • SAMLS临床参数阈值:年龄>45岁、白细胞计数<1.5或>30.0×10³/μL、白蛋白<3.8 g/dL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2017 European LeukemiaNet 2017 acute myeloid leukemia (AML) risk stratification (ELN2017) is widely used for risk-stratifying patients with AML. However, its applicability in low- and middle-income countries is limited because of a lack of full cytogenetic and molecular information at diagnosis. Here, we propose an alternative for risk stratification (the Adapted Genetic Risk [AGR]), which permits cytogenetic or molecular missing data while retaining prognostic power. We first analyzed 167 intensively treated patients with nonacute promyelocytic leukemia AML enrolled in São Paulo, Brazil (Faculdade de Medicina da Universidade de São Paulo), as our training data set, using ELN2017 as the standard for comparison with our AGR. Next, we combined our AGR with clinical prognostic parameters found in a Cox proportional hazards model to create a novel scoring system (survival AML score, SAMLS) that stratifies patients with newly diagnosed AML. Finally, we have used 2 independent test cohorts, Faculdade de Medicina de Ribeirão Preto (FMRP; Brazil, n = 145) and Oxford University Hospitals (OUH; United Kingdom, n = 157) for validating our findings. AGR was statistically significant for overall survival (OS) in both test cohorts (FMRP, P = .037; OUH, P = .012) and disease-free survival in FMRP (P = .04). The clinical prognostic features in SAMLS were age (>45 years), white blood cell count (<1.5 or >30.0 × 103/μL), and low albumin levels (<3.8 g/dL), which were associated with worse OS in all 3 cohorts. SAMLS showed a significant difference in OS in the training cohort (P < .001) and test cohorts (FMRP, P = .0018; OUH, P < .001). Therefore, SAMLS, which incorporates the novel AGR evaluation with clinical parameters, is an accurate tool for AML risk assessment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Silveira DRA, Quek L, Santos IS, et al. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 2020. PMID: 32453839. doi:10.1182/bloodadvances.2019001419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。